About Avanos Medical, Inc.
https://avanos.comAvanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
CEO
Sigfrido Delgado
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 144
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:7.01M
Value:$83.22M
BLACKROCK, INC.
Shares:6.83M
Value:$81.12M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:4.71M
Value:$55.95M
Summary
Showing Top 3 of 345
About Avanos Medical, Inc.
https://avanos.comAvanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $177.8M ▲ | $68M ▼ | $-1.4M ▲ | -0.79% ▲ | $-0.03 ▲ | $10M ▲ |
| Q2-2025 | $175M ▲ | $84.8M ▲ | $-76.8M ▼ | -43.89% ▼ | $-1.66 ▼ | $-63.9M ▼ |
| Q1-2025 | $167.5M ▼ | $82.5M ▼ | $6.6M ▲ | 3.94% ▲ | $0.14 ▲ | $21.4M ▲ |
| Q4-2024 | $179.6M ▲ | $86.8M ▲ | $-397.3M ▼ | -221.21% ▼ | $-8.64 ▼ | $-406.6M ▼ |
| Q3-2024 | $170.4M | $76.2M | $4.3M | 2.52% | $0.09 | $24.4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $70.5M ▼ | $1.07B ▲ | $289.7M ▲ | $778M ▲ |
| Q2-2025 | $90.3M ▼ | $1.04B ▼ | $262.7M ▼ | $776.3M ▼ |
| Q1-2025 | $97M ▼ | $1.11B ▼ | $268.4M ▼ | $839.4M ▲ |
| Q4-2024 | $107.7M ▲ | $1.15B ▼ | $325.7M ▼ | $828.5M ▼ |
| Q3-2024 | $89M | $1.66B | $426.5M | $1.23B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.4M ▲ | $14M ▲ | $-31.5M ▼ | $-2M ▲ | $-19.8M ▼ | $7M ▲ |
| Q2-2025 | $-76.8M ▼ | $6.8M ▼ | $-13.2M ▼ | $-3.2M ▲ | $-6.7M ▲ | $-4.2M ▼ |
| Q1-2025 | $6.6M ▲ | $25.7M ▼ | $-9.1M ▼ | $-29.1M ▼ | $-10.7M ▼ | $19M ▼ |
| Q4-2024 | $-397.3M ▼ | $57.9M ▲ | $-7.6M ▲ | $-27.4M ▼ | $18.7M ▲ | $53.1M ▲ |
| Q3-2024 | $4.3M | $23M | $-12M | $-16M | $-3.2M | $20M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Corporate Other | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
 Digestive Health | $110.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Sigfrido Delgado
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 144
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:7.01M
Value:$83.22M
BLACKROCK, INC.
Shares:6.83M
Value:$81.12M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:4.71M
Value:$55.95M
Summary
Showing Top 3 of 345